Adam Schoen

Background

About Adam Schoen

I am an intellectual property partner and co-practice group leader of Brown Rudnick’s Global Intellectual Property Practice Group and Global Life Sciences Group. I have more than two decades of experience advising life sciences and medical device funds, companies, and academic institutions while helping my clients build, grown, invest in, buy, and sell companies of all sizes over the world. Select Representations: • Acelyrin in its $540 million IPO, one of the largest U.S. IPOs by a traditional biopharma company • Latigo Biotherapeutics in a $135 million Series A financing to develop nonopioid pain medication • Kate Therapeutics in its exclusive licensing deal with Astellas Pharma to develop and commercialize a gene therapy for a debilitating muscle disorder. I am ranked as a leading life sciences lawyer in The Legal 500 US.